iSpecimen Overview
Compare iSpecimen's DCF valuation ($-2) to today's market price.
Get informed when a big investor buys or sells
+ Follow$-1.97
Overvalued by 227.8% based on the discounted cash flow analysis.
The latest DCF fair value for ISPC is $-2. Investors often review this figure alongside iSpecimen's historical trend and sector peers before judging valuation or financial health.
A DCF fair value of $-2 for iSpecimen suggests the stock may be overvalued by roughly 227.8% at today's price. That does not mean the market is 'wrong'; it means the model's cash-flow assumptions imply a different intrinsic value. Stress-test the estimate by comparing it with historical valuation ranges and peer multiples.
After noting ISPC's DCF fair value ($-2), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack iSpecimen's DCF fair value against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
